Skip to main content

Table 2 eRAPID RT study questionnaires and Case Report Forms (CRFs): participant completed

From: eRAPID electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: a pilot study protocol in pelvic radiotherapy

Questionnaire/CRF Description of time points for completion Baseline 3 weeks 6 weeks 9 weeks 12 weeks 18 weeks 24 weeks
Consent form Baseline X       
Baseline: patient sociodemographic data form Baseline X       
Baseline: computer usage questionnaire Baseline X       
Patient-reported eRAPID symptom questionnaire
(eRAPID intervention arm only)
Within 24 h of study entry and weekly during treatment and 6 weeks afterwards (12 weeks total). Then at 18 and 24 weeks. X weekly X weekly X weekly X weekly X weekly X (except rectal) X (except rectal)
Patient Outcome Measures
 FACT-G
 EORTC-QLQ-C30
 EQ-5D-5 L
Baseline, 6, 12 and 24 weeks X   X   X   X
 Self-efficacy, Lorig 6-item Baseline and 12 weeks X     X   
 Patient Activation Measure (PAM) Baseline and 12 weeks X     X   
 Use of resources form 6, 12 and 24 weeks    X   X   X
 System Usability Scale 24 weeks (eRAPID intervention arm only)        X
Participant withdrawal feedback form At point of withdrawal        
End of study patient questionnaire 24 weeks        X
Clinician questionnaires
 Clinician eRAPID feedback form (eRAPID intervention arm only) At routine hospital appointments throughout the study   X X X X X (except rectal) X (except rectal)
 Clinician record of CTCAE To be completed by clinician at the follow-up appointment 4–6 weeks after completion of treatment (exact time-point will be different for different disease groups)